Switzerland's Medartis Holding AG said Feb. 27 that it is planning an IPO on the SIX Swiss Exchange in the first half of 2018.
The bone implant manufacturer will use proceeds to finance its growth and help raise its international profile.
For 2017, Medartis posted operational EBITDA of CHF19 million, with net revenues of CHF105 million, up 14% year over year.
Vischer AG is acting as legal counsel to Medartis, with Davis Polk assisting on U.S. securities law matters and Quarton International AG as financial adviser.
Zürcher Kantonalbank and Bryan Garnier & Co. are acting as underwriters, joint global coordinators and Joint book runners for the planned IPO, with Kepler Cheuvreux as underwriter and co-manager. Walder Wyss AG is acting as legal counsel to the underwriters.
